38862-65-6

Basic information

• Product Name: BENZOIC ACID, 2,4-DIHYDROXY-6-PENTYL-, ETHYL ESTER
• Synonyms: BENZOIC ACID, 2,4-DIHYDROXY-6-PENTYL-, ETHYL ESTER;ethyl 2,4-dihydroxy-6-pentylbenzoate;Ethyl Olivetolate
• CAS NO: 38862-65-6
• Molecular Formula: C₁₄H₂₀O₄
• Molecular Weight: 252.31
• Mol File: 38862-65-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 69 °C
• Boiling Point: 420.4±30.0 °C(Predicted)
• Appearance: /
• Density: 1.131±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 8.30±0.23(Predicted)
• CAS DataBase Reference: BENZOIC ACID, 2,4-DIHYDROXY-6-PENTYL-, ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOIC ACID, 2,4-DIHYDROXY-6-PENTYL-, ETHYL ESTER(38862-65-6)
• EPA Substance Registry System: BENZOIC ACID, 2,4-DIHYDROXY-6-PENTYL-, ETHYL ESTER(38862-65-6)

Safety Data

• Hazardous Substances Data: 38862-65-6(Hazardous Substances Data)

Usage

Uses

Ethyl Olivetolate is used for preparation of crystalline Cannabidiol for pharmaceutical formulations.

Upstream product

• 674-82-8 4-methyleneoxetan-2-one 
• 10488-95-6 ethyl 3-oxooctanoate 
• 64-17-5 ethanol 
• 58497-40-8 3,5-dibromo-2,4-dihydroxy-6-n-pentylbenzoic acid ethyl ester 
• 641-68-9 anziaic acid 

Downstream Products

• 86791-42-6 ethyl 2-hydroxy-6-pentyl-4-(1-phenyl-5-tetrazolyl)-oxybenzoate 
• 201344-49-2 3-Chloro-4,6-dihydroxy-2-pentyl-benzoic acid ethyl ester 
• 43009-38-7 (6aS,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol 
• 3556-78-3 cannabidiol 
• 16849-50-6 tetrahydrocannabinol 
• 14132-18-4 6,6,9-Trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol 
• 6909-05-3 iso-Δ⁸-tetrahydrocannabinol 
• 13956-29-1 CBD 
• 491-72-5 2,4-dihydroxyl-6-pentylbenzoic acid 
• 86791-43-7 ethyl 2-hydroxy-6-pentylbenzoate 
• 83326-76-5 C_5:0-anacardic acid 
• 104307-61-1 benzyl 2,4-di-O-benzylimbricarate 
• 104307-63-3 benzyl 3,5-dichloro-2'-O-methylanziate 
• 67121-42-0 4-O-demethylimbricaric acid 

Relevant articles and documents

Crystalline Form of Cannabidiol

Crystalline Cannabidiol of a novel form, including (R,R)-(?)-crystalline Cannabidiol, as well as methods of making such novel form of Cannabidiol, pharmaceutical formulations comprising such novel form of Cannabidiol, and methods of treating diseases with such novel form of Cannabidiol.

Inhibition of prostaglandin biosynthesis by 4-O-methylcryptochlorophaeic acid; synthesis of monomeric arylcarboxylic acids for inhibitory activity testing and X-ray analysis of 4-O-methylcryptochlorophaeic acid

In order to clarify the structure-activity relationship of 4-O-methylcryptochlorophaeic acid (1), which is a lichen meta-depside and a potent inhibitor of prostaglandin (PG) biosynthesis found in our previous screening work, arylcarboxylic acids (5-8) corresponding to the monomeric moieties of 4-O-methylcryptochlorophaeic acid (1) were synthesized and tested for inhibitory effect against PG biosynthesis by an enzyme system prepared from rabbit renal medulla. They were a hundred times less active that 4-O-methylcryptochlorophaeic acid (1), indicating that the dimeric structure of the meta-depside is essential for inhibitory activity against PG biosynthesis. Kinetic studies on the mechanism of inhibition revealed that 4-O-methylcryptochlorophaeic acid (1) inhibits PG biosynthesis competitively with respect to the substrate, arachidonic acid. The three dimensional structure of 4-O-methylcryptochlorophaeic acid (1), which is expected to have a molecular structure able to fit into an active site that accommodates arachidonic acid, was determined by single crystal X-ray analysis with the direct approach. The obtained structure reveals that 4-O-methylcryptochlorophaeic acid (1) maintains a rigid conformation by forming a strong hydrogen bond between a hydroxy group and a methoxy group. Based on these findings, a new active site model of fatty acid cylooxygenase is proposed in order to explain the inhibition by the meta-depside and acidic non-steroidal antiinflammatory drugs.